Engineers from the University of Pennsylvania and Rice University have developed an improved base editor that can edit individual genetic base pairs to a new level of precision, opening the door to safer, more reliable therapies for a wide range of genetic diseases, including cystic fibrosis.
Genetic disorders often demand tailored therapies due to their unique mutations. According to Xue “Sherry” Gao, senior author on the paper published in Molecular Therapy, “More than a thousand different genetic mutations can cause cystic fibrosis.”
To treat conditions like cystic fibrosis, researchers need to develop a suite of tools, rather than a single therapy. But even when scientists know exactly which DNA letter they want to change, current gene-editing technologies can unintentionally alter nearby letters as well, introducing “bystander” mutations that raise safety concerns.
A key challenge involves C-to-T errors where multiple cytosine pairs appear close together, affecting most relevant disease mutations. Tyler C. Daniel, co-first author, explained, “In some cases, the letter should be a T. Instead, it’s a C, which can impair or completely abolish the function of the gene, leading to disease.” The team addressed this by redesigning the editor's linker, which connects its targeting and editing parts. Shortening and stiffening it limited the enzyme's range, as Daniel described: “We essentially tightened the leash to ensure only our target was edited.” They also reduced the editor's grip on nearby DNA.
Lab tests in human cells showed the improved editor cut bystander mutations by over 80% at target sites while keeping high editing efficiency. For cystic fibrosis models, it reversed mutations in lung-relevant epithelial cells, restoring function. Gang Bao, co-senior author, said, “We were able to reverse those mutations and show improved cellular functions using the same editor, demonstrating the level of pinpoint gene-editing control this technology now offers.”
At cystic fibrosis sites, off-target edits fell from 50–60% to under 1%, preserving intended fixes. This one-time correction approach contrasts with daily drugs like Trikafta, which carry high costs. Bao emphasized, “The more precise we can make these tools, the greater their potential to change how we treat genetic disease.”
Publication details: Zeng, Hongzhi, et al. Precision A3G base editors for disease modeling and correction. Molecular Therapy. January 13, 2026
Genetic disorders often demand tailored therapies due to their unique mutations. According to Xue “Sherry” Gao, senior author on the paper published in Molecular Therapy, “More than a thousand different genetic mutations can cause cystic fibrosis.”
To treat conditions like cystic fibrosis, researchers need to develop a suite of tools, rather than a single therapy. But even when scientists know exactly which DNA letter they want to change, current gene-editing technologies can unintentionally alter nearby letters as well, introducing “bystander” mutations that raise safety concerns.
A key challenge involves C-to-T errors where multiple cytosine pairs appear close together, affecting most relevant disease mutations. Tyler C. Daniel, co-first author, explained, “In some cases, the letter should be a T. Instead, it’s a C, which can impair or completely abolish the function of the gene, leading to disease.” The team addressed this by redesigning the editor's linker, which connects its targeting and editing parts. Shortening and stiffening it limited the enzyme's range, as Daniel described: “We essentially tightened the leash to ensure only our target was edited.” They also reduced the editor's grip on nearby DNA.
Lab tests in human cells showed the improved editor cut bystander mutations by over 80% at target sites while keeping high editing efficiency. For cystic fibrosis models, it reversed mutations in lung-relevant epithelial cells, restoring function. Gang Bao, co-senior author, said, “We were able to reverse those mutations and show improved cellular functions using the same editor, demonstrating the level of pinpoint gene-editing control this technology now offers.”
At cystic fibrosis sites, off-target edits fell from 50–60% to under 1%, preserving intended fixes. This one-time correction approach contrasts with daily drugs like Trikafta, which carry high costs. Bao emphasized, “The more precise we can make these tools, the greater their potential to change how we treat genetic disease.”
Publication details: Zeng, Hongzhi, et al. Precision A3G base editors for disease modeling and correction. Molecular Therapy. January 13, 2026